SELLAS Life Sciences Group, Inc. SLS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about SELLAS Life Sciences Group, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s cash & equivalents?
- SELLAS Life Sciences Group, Inc. (SLS) reported cash & equivalents of $107.1M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s cash & equivalents changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s cash & equivalents increased by 277.1% year-over-year, from $28.4M to $107.1M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s cash & equivalents has grown at a 15.3% compound annual growth rate (CAGR), from $35.3M to $71.79M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.